Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2026-03-04 Transaction in Own Shar…
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Hikma Pharmaceuticals PLC regarding 'TRANSACTIONS IN OWN SHARES'. It details the purchase of its own ordinary shares as part of a previously announced share repurchase programme, including specific trade data, dates, prices, and the impact on treasury shares and total voting rights. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2026-03-04 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Hikma Pharmaceuticals PLC regarding 'TRANSACTIONS IN OWN SHARES'. It details the purchase of ordinary shares as part of a share repurchase programme, including specific trade dates, volumes, prices, and venue information. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2026-03-03 English
Total Voting Rights
Regulatory Filings Classification · 100% confidence The document is a standard regulatory notification regarding 'Total Voting Rights and Capital' issued by Hikma Pharmaceuticals PLC in accordance with the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules. It provides the total number of voting shares and treasury shares as of a specific date. This type of filing is a routine regulatory disclosure required by stock exchanges and does not fit into specific categories like M&A, dividends, or financial reports. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-02 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Hikma Pharmaceuticals PLC regarding the purchase of its own shares (share buyback) on the London Stock Exchange. It provides specific details on the number of shares, prices paid, and the total number of voting rights, which is a standard regulatory disclosure for share repurchases. This fits the definition of 'Transaction in Own Shares' (POS).
2026-03-02 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Hikma Pharmaceuticals PLC regarding the purchase of its own shares (share buyback) on the London Stock Exchange. It provides detailed transaction data, including dates, volumes, and prices, in accordance with regulatory requirements (Article 5(1)(b) of Regulation (EU) No 596/2014). This fits the definition of 'Transaction in Own Shares' (POS).
2026-02-27 English
Launch of Buyback Programme
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Hikma Pharmaceuticals Plc dated 26 February 2026 regarding the launch of a share buyback programme. It details the size, purpose, and execution plan of the buyback, including the involvement of financial institutions and regulatory compliance. The text does not contain financial statements or detailed financial performance data but rather focuses on the company's capital structure change through repurchasing its own shares. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements. The document length is over 6,000 characters, indicating it is a full announcement rather than a brief note or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2026-02-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.